公开(公告)号：US20110201108A1

公开(公告)日：2011-08-18

申请号：US13094577

申请日：2011-04-26

Applicant: Martin FRIEDLANDER ,  Matthew R. Ritter ,  Stacey K. Moreno

Inventor： Martin FRIEDLANDER ,  Matthew R. Ritter ,  Stacey K. Moreno

IPC: C12N5/078

CPC classification number: C12N5/0647 ,  A61K2035/124 ,  C12N5/0692

Abstract: The present invention provides an isolated myeloid-like bone marrow cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen and CD11b antigen. These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like bone marrow cells are isolated by treating bone marrow cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, or against both and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.

Abstract translation: 本发明提供了分离的骨髓样骨髓细胞群，其包含谱系阴性的大多数细胞，并表达CD44抗原和CD11b抗原。 当眼内施用于哺乳动物，特别是患有眼变性疾病的哺乳动物的眼睛时，这些细胞具有有益的血管营养和神经营养活性。 通过用针对CD11b的抗CD44抗体（透明质酸受体）或针对两者的方法处理骨髓细胞来分离骨髓样细胞，并使用流式细胞术从其中阳性选择表达CD44和/或CD11b的细胞。 本发明的分离的骨髓样骨髓细胞可以用编码治疗有用的蛋白质的基因转染，用于将该基因递送至视网膜。

公开(公告)号：US07931891B2

公开(公告)日：2011-04-26

申请号：US11884958

申请日：2006-02-24

Applicant: Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno

Inventor： Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno

IPC: A01N65/00 ,  A01N1/02 ,  A01K48/00

CPC classification number: C12N5/0647 ,  A61K2035/124 ,  C12N5/0692

Abstract: The present invention provides an isolated myeloid-like cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen, CD11b antigen, and hypoxia inducible factor 1 α (HIF-1 α). These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like cells are isolated by treating bone marrow cells, peripheral blood cells or umbilical cord cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, CD14, CD33, or against a combination thereof and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.

Abstract translation: 本发明提供了分离的骨髓样细胞群，其包含谱系阴性的大部分细胞，并表达CD44抗原，CD11b抗原和缺氧诱导因子1α（HIF-1α）。 当眼内施用于哺乳动物，特别是患有眼变性疾病的哺乳动物的眼睛时，这些细胞具有有益的血管营养和神经营养活性。 通过用针对CD44（透明质酸受体）的抗体对CD11b，CD14，CD33或其组合处理骨髓细胞，外周血细胞或脐带细胞来分离骨髓样细胞，并使用流式细胞术积极选择 CD44和/或CD11b表达细胞。 本发明的分离的骨髓样骨髓细胞可以用编码治疗有用的蛋白质的基因转染，用于将该基因递送至视网膜。

公开(公告)号：US20120009166A1

公开(公告)日：2012-01-12

申请号：US13136940

申请日：2011-08-15

Applicant: Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno ,  Mohammad A. El-Kalay

Inventor： Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno ,  Mohammad A. El-Kalay

IPC: A61K35/28 ,  A61K35/12 ,  G01N33/566 ,  A61P27/02 ,  A61P9/00 ,  A61P27/06 ,  C12N5/0786 ,  A61K35/14

CPC classification number: C12N5/0645 ,  A61K2035/124 ,  C12N2501/052

Abstract: The invention provides methods of using isolated monocyte populations to treat subjects suffering from various ocular vascular disease or ocular degenerative disorders. The present invention also provides novel methods for isolating substantially pure monocyte populations. The methods involve extracting a blood sample or a bone marrow sample from a subject, debulking red blood cells from the sample, and then separating remaining red blood cells and other cell types in the sample from monocytes. Instead of using any selection or labeling agents, the red blood cells and other cell types are separated from monocytes based on their size, granularity or density. The isolated monocytes can be further activated in vitro or ex vivo prior to being administered to a subject. Isolated cell populations containing substantially pure CD14+/CD33+ monocytes are also provided in the invention.

Abstract translation: 本发明提供使用分离的单核细胞群体来治疗患有各种眼血管疾病或眼部退行性疾病的受试者的方法。 本发明还提供了用于分离基本上纯的单核细胞群体的新方法。 所述方法包括从受试者提取血液样品或骨髓样品，从样品中减量红细胞，然后从单核细胞中分离样品中剩余的红细胞和其它细胞类型。 根据其大小，粒度或密度，红细胞和其他细胞类型与单核细胞分离而不是使用任何选择或标记试剂。 分离的单核细胞可以在给予受试者之前在体外或体外进一步活化。 在本发明中也提供了含有基本上纯的CD14 + / CD33 +单核细胞的分离的细胞群。

公开(公告)号：US20100254952A1

公开(公告)日：2010-10-07

申请号：US12658440

申请日：2010-02-05

Applicant: Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno ,  Valentina Marchetti

Inventor： Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno ,  Valentina Marchetti

IPC: A61K35/12 ,  A61P27/02 ,  A61P9/00

CPC classification number: C12N5/0647 ,  A61K2035/124 ,  C12N5/0692

Abstract: The present invention provides a method of rebuilding and stabilizing functional vasculature in hypoxic retinal tissue comprising contacting the hypoxic retinal tissue with an effective amount of cells from an isolated myeloid-like cell population comprising a majority of cells that express CD44 antigen, CD11b antigen, and hypoxia inducible factor 1α (HIF-1α). The isolated myeloid-like bone marrow cells optionally can be transfected with a gene encoding a therapeutically useful peptide, for delivering the gene to the retina.

Abstract translation: 本发明提供了一种在缺氧视网膜组织中重建和稳定功能性脉管系统的方法，其包括使缺氧视网膜组织与来自分离的骨髓样细胞群的有效量的细胞接触，所述细胞包含大部分表达CD44抗原，CD11b抗原和 缺氧诱导因子1α（HIF-1α）。 分离的骨髓样骨髓细胞任选地可以用编码治疗有用的肽的基因转染，用于将基因递送到视网膜。

公开(公告)号：US20080194018A1

公开(公告)日：2008-08-14

申请号：US11884958

申请日：2006-02-24

Applicant: Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno

Inventor： Martin Friedlander ,  Matthew R. Ritter ,  Stacey K. Moreno

IPC: C12N5/08 ,  C12N5/06

CPC classification number: C12N5/0647 ,  A61K2035/124 ,  C12N5/0692

Abstract: The present invention provides an isolated myeloid-like bone marrow cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen and CD11b antigen. These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like bone marrow cells are isolated by treating bone marrow cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, or against both and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.

Abstract translation: 本发明提供了分离的骨髓样骨髓细胞群，其包含谱系阴性的大多数细胞，并表达CD44抗原和CD11b抗原。 当眼内施用于哺乳动物，特别是患有眼变性疾病的哺乳动物的眼睛时，这些细胞具有有益的血管营养和神经营养活性。 通过用针对CD11b的抗CD44抗体（透明质酸受体）或针对两者的方法处理骨髓细胞来分离骨髓样细胞，并使用流式细胞术从其中阳性选择表达CD44和/或CD11b的细胞。 本发明的分离的骨髓样骨髓细胞可以用编码治疗有用的蛋白质的基因转染，用于将该基因递送至视网膜。